Pacific Biosciences of California Inc PACB.OQ PACB.O is expected to show a fall in quarterly revenue when it reports results on May 8 for the period ending March 31 2025
The Menlo Park California-based company is expected to report a 10.3% decrease in revenue to $34.81 million from $38.81 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
LSEG's mean analyst estimate for Pacific Biosciences of California Inc is for a loss of 19 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 0.5% in the last three months.
Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00, above its last closing price of $1.11.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.21 | -0.21 | -0.49 | Missed | -138.6 |
Sep. 30 2024 | -0.24 | -0.22 | -0.22 | Met | 2 |
Jun. 30 2024 | -0.24 | -0.23 | -0.64 | Missed | -175.1 |
Mar. 31 2024 | -0.28 | -0.28 | -0.29 | Missed | -5.3 |
Dec. 31 2023 | -0.29 | -0.29 | -0.31 | Missed | -8.7 |
Sep. 30 2023 | -0.34 | -0.33 | -0.26 | Beat | 20.8 |
Jun. 30 2023 | -0.32 | -0.32 | -0.28 | Beat | 12.7 |
Mar. 31 2023 | -0.33 | -0.33 | -0.36 | Missed | -8.3 |
This summary was machine generated May 6 at 21:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)